MY200479A - A crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid - Google Patents
A crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroidInfo
- Publication number
- MY200479A MY200479A MYPI2019000844A MYPI2019000844A MY200479A MY 200479 A MY200479 A MY 200479A MY PI2019000844 A MYPI2019000844 A MY PI2019000844A MY PI2019000844 A MYPI2019000844 A MY PI2019000844A MY 200479 A MY200479 A MY 200479A
- Authority
- MY
- Malaysia
- Prior art keywords
- disubstituted
- formula
- crystalline
- pyrazolyl steroid
- steroid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378582P | 2016-08-23 | 2016-08-23 | |
| PCT/US2017/048267 WO2018039378A1 (fr) | 2016-08-23 | 2017-08-23 | Stéroïde c21-n-pyrazolyle 3-disubstitué en 19-nor c3 cristallin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY200479A true MY200479A (en) | 2023-12-28 |
Family
ID=59772778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019000844A MY200479A (en) | 2016-08-23 | 2017-08-23 | A crystalline 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US11236121B2 (fr) |
| EP (2) | EP3981763A1 (fr) |
| JP (3) | JP2019524853A (fr) |
| KR (2) | KR20230079470A (fr) |
| CN (4) | CN115974956A (fr) |
| AR (3) | AR109393A1 (fr) |
| AU (3) | AU2017315682B2 (fr) |
| BR (1) | BR112019003637A2 (fr) |
| CA (1) | CA3034262A1 (fr) |
| CL (2) | CL2019000477A1 (fr) |
| CO (1) | CO2019002596A2 (fr) |
| EA (1) | EA201990565A1 (fr) |
| EC (1) | ECSP19020141A (fr) |
| IL (2) | IL302480A (fr) |
| JO (1) | JOP20190022B1 (fr) |
| MA (1) | MA46042A (fr) |
| MX (2) | MX393240B (fr) |
| MY (1) | MY200479A (fr) |
| NZ (1) | NZ791594A (fr) |
| PE (2) | PE20241580A1 (fr) |
| PH (1) | PH12019500375A1 (fr) |
| SG (1) | SG11201901445TA (fr) |
| TW (2) | TWI854445B (fr) |
| WO (1) | WO2018039378A1 (fr) |
| ZA (1) | ZA201901051B (fr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2766380T (pt) | 2011-10-14 | 2019-07-29 | Sage Therapeutics Inc | Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos |
| EP2887944B1 (fr) | 2012-08-21 | 2021-10-06 | Sage Therapeutics, Inc. | Allopregnanolone pour le traitement du status épileptique réfractaire |
| WO2014169831A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-hétéroaryl-stéroïdes c21-c-liés c3,3-disubstitués et procédés d'utilisation de ceux-ci |
| KR102614507B1 (ko) | 2013-04-17 | 2023-12-19 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| WO2014169836A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-stéroïdes neuroactifs et procédés d'utilisation de ceux-ci |
| PL2986624T3 (pl) | 2013-04-17 | 2020-11-16 | Sage Therapeutics, Inc. | Neuroaktywne steroidy 19-NOR do stosowania w sposobach leczenia |
| CA3199003A1 (fr) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Steroides neuroactifs, compositions, et leurs utilisations |
| HUE052308T2 (hu) | 2013-08-23 | 2021-04-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásuk |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| EP3206493B1 (fr) | 2014-10-16 | 2020-05-06 | Sage Therapeutics, Inc. | Compositions et méthodes pour traiter des troubles du snc |
| CN117024502A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| EP3719029A1 (fr) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions pour l'induction de la sédation |
| ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| KR20230079470A (ko) | 2016-08-23 | 2023-06-07 | 세이지 테라퓨틱스, 인크. | 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
| US20200281943A1 (en) * | 2017-09-07 | 2020-09-10 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| IL303083A (en) * | 2017-09-14 | 2023-07-01 | Sage Therapeutics Inc | 19-NOR C3,3-C21-N-pyrazolyl steroid dimer and methods of using it |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| CN117959309A (zh) * | 2018-06-12 | 2024-05-03 | 萨奇治疗股份有限公司 | 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| MX2021006618A (es) | 2018-12-05 | 2021-09-23 | Sage Therapeutics Inc | Esteroides neuroactivos y sus metodos de uso. |
| CN111454318A (zh) * | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| CN111770915A (zh) * | 2019-01-31 | 2020-10-13 | 深圳仁泰医药科技有限公司 | γ-氨基丁酸调节剂的晶型X及其制备方法和应用 |
| US20220220149A1 (en) | 2019-05-28 | 2022-07-14 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
| WO2020243488A1 (fr) | 2019-05-31 | 2020-12-03 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs et compositions associées |
| US20220275020A1 (en) * | 2019-08-07 | 2022-09-01 | Shanghai Hansoh Biomedical Co., Ltd. | Salt and crystal form of steroid derivative regulator |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| EP4125921A1 (fr) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Utilisation d'agents pour le traitement d'affections respiratoires |
| BR112023000990A2 (pt) * | 2020-07-20 | 2023-03-28 | Sage Therapeutics Inc | Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas |
| WO2022072620A1 (fr) * | 2020-10-01 | 2022-04-07 | Eliem Therapeutics (UK) Ltd | Méthodes de traitement de la fibromyalgie à l'aide de stéroïdes neuroactifs |
| JP2024507638A (ja) | 2021-01-28 | 2024-02-21 | セージ セラピューティクス， インコーポレイテッド | 性機能障害処置のための神経刺激性ステロイドの使用 |
| CA3213744A1 (fr) | 2021-03-17 | 2022-09-22 | Sage Therapeutics, Inc. | Steroide 19-nor c3,3-disubstitue c21-n-pyrazolyl pour le traitement d'un trouble depressif majeur |
| WO2022232494A1 (fr) | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | Stéroïde neuroactif destiné à être utilisé dans le traitement d'un trouble dépressif majeur et de la dépression post-partum chez une femme allaitante |
| IL307991A (en) | 2021-04-29 | 2023-12-01 | Sage Therapeutics Inc | 19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression |
| KR20240037975A (ko) | 2021-07-28 | 2024-03-22 | 세이지 테라퓨틱스, 인크. | 신경활성 스테로이드의 결정질 형태 |
| KR20240148425A (ko) | 2022-02-16 | 2024-10-11 | 세이지 테라퓨틱스, 인크. | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 |
| TW202341996A (zh) | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療腸胃疾病或病狀之神經活性類固醇 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| AU2930501A (en) * | 2000-01-07 | 2001-07-24 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| CN1323074C (zh) | 2002-02-08 | 2007-06-27 | 小野药品工业株式会社 | 哌啶衍生物以及包含哌啶衍生物作为活性成分的药物组合物 |
| WO2011079047A1 (fr) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Procédés pour réduire l'occurrence d'accouchements prématurés et d'autres conditions associées à une grossesse |
| CA2843436A1 (fr) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Nouveaux steroides substitues en 17? par un heteroaryle, capables de moduler les recepteurs gabaa |
| WO2013043985A1 (fr) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Huiles comestibles favorisant l'administration de stéroïdes administrés par voie orale |
| PT2766380T (pt) | 2011-10-14 | 2019-07-29 | Sage Therapeutics Inc | Compostos de 19-nor pregnano 3,3-dissubstituídos, composições e seus usos |
| RS59734B1 (sr) | 2012-01-23 | 2020-02-28 | Sage Therapeutics Inc | Formulacije neuroaktivnog steroida koje uključuju kompleks alopregnanolona i sulfobutil etar beta-ciklodekstrina |
| WO2013188792A2 (fr) | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs, compositions, et leurs utilisations |
| WO2014028398A2 (fr) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation de crises épileptiques par une polythérapie à l'aide de benzodiazépines et de neurostéroïdes |
| EP2887944B1 (fr) | 2012-08-21 | 2021-10-06 | Sage Therapeutics, Inc. | Allopregnanolone pour le traitement du status épileptique réfractaire |
| WO2014058736A1 (fr) | 2012-10-08 | 2014-04-17 | Washington University | Stéroïdes neuroactifs 19-alcoxy-17(20)-z-vinylcyano-substitués, promédicaments associés et méthodes de traitement les utilisant |
| EP2925327B1 (fr) | 2012-11-30 | 2024-01-10 | The Regents of The University of California | Allopregnanolone pour le traitement, la reduction or l'adouccissement des symptômes de la dépression post partum |
| KR102400891B1 (ko) | 2012-12-18 | 2022-05-20 | 워싱톤 유니버시티 | 신경활성 19-알콕시-17-치환된 스테로이드, 그의 전구약물, 및 그를 사용한 치료 방법 |
| WO2014169836A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-stéroïdes neuroactifs et procédés d'utilisation de ceux-ci |
| KR102614507B1 (ko) | 2013-04-17 | 2023-12-19 | 세이지 테라퓨틱스, 인크. | 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| WO2014169831A1 (fr) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor-hétéroaryl-stéroïdes c21-c-liés c3,3-disubstitués et procédés d'utilisation de ceux-ci |
| PL2986624T3 (pl) | 2013-04-17 | 2020-11-16 | Sage Therapeutics, Inc. | Neuroaktywne steroidy 19-NOR do stosowania w sposobach leczenia |
| CA3199003A1 (fr) | 2013-07-19 | 2015-01-22 | Sage Therapeutics, Inc. | Steroides neuroactifs, compositions, et leurs utilisations |
| HUE052308T2 (hu) | 2013-08-23 | 2021-04-28 | Sage Therapeutics Inc | Neuroaktív szteroidok, készítmények és alkalmazásuk |
| ES2927007T3 (es) | 2014-05-29 | 2022-10-31 | Sage Therapeutics Inc | Esteroides neuroactivos, composiciones y usos de los mismos |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| CN117024502A (zh) | 2014-10-16 | 2023-11-10 | 萨奇治疗股份有限公司 | 靶向cns障碍的组合物和方法 |
| EP3206493B1 (fr) | 2014-10-16 | 2020-05-06 | Sage Therapeutics, Inc. | Compositions et méthodes pour traiter des troubles du snc |
| EP3719029A1 (fr) | 2014-11-27 | 2020-10-07 | Sage Therapeutics, Inc. | Compositions pour l'induction de la sédation |
| ES2857082T3 (es) | 2015-01-26 | 2021-09-28 | Sage Therapeutics Inc | Composiciones y métodos para el tratamiento de trastornos del SNC |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| US20180311258A1 (en) | 2015-04-10 | 2018-11-01 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| EP3347368A4 (fr) | 2015-09-08 | 2019-01-23 | Viewpoint Therapeutics, Inc. | Composés et formulations pour traiter les maladies ophthalmiques |
| EA036155B1 (ru) | 2015-10-16 | 2020-10-06 | Маринус Фармасьютикалс, Инк. | Инъекционные составы нейростероида, содержащие наночастицы |
| WO2017087864A1 (fr) | 2015-11-20 | 2017-05-26 | Sage Therapeutics, Inc. | Composés et leurs méthodes d'utilisation |
| AU2017229656B2 (en) | 2016-03-08 | 2022-09-29 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| KR20230079470A (ko) | 2016-08-23 | 2023-06-07 | 세이지 테라퓨틱스, 인크. | 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (fr) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | Méthodes de traitement de l'épilepsie et d'affections associées à kcnti |
| CA3073925A1 (fr) | 2017-08-31 | 2019-03-07 | Takeda Pharmaceutical Company Limited | Traitement d'affections du snc |
| US20200281943A1 (en) | 2017-09-07 | 2020-09-10 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| WO2019051477A1 (fr) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | Méthodes de traitement de l'épilepsie ou de l'état de mal épileptique |
| IL303083A (en) | 2017-09-14 | 2023-07-01 | Sage Therapeutics Inc | 19-NOR C3,3-C21-N-pyrazolyl steroid dimer and methods of using it |
| US20190160078A1 (en) | 2017-11-10 | 2019-05-30 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disorders |
| KR20200096596A (ko) | 2017-12-08 | 2020-08-12 | 세이지 테라퓨틱스, 인크. | Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체 |
| JP2021506904A (ja) | 2017-12-22 | 2021-02-22 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害の処置のための組成物および方法 |
| EP3728284B1 (fr) | 2017-12-22 | 2024-08-21 | Sage Therapeutics, Inc. | Composés 19-homo, 3.alpha.-hydroxy-stéroïde-20-ones pour le traitement des troubles du snc |
| JP7538040B2 (ja) | 2018-01-12 | 2024-08-21 | セージ セラピューティクス， インコーポレイテッド | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
| CN117959309A (zh) | 2018-06-12 | 2024-05-03 | 萨奇治疗股份有限公司 | 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| JP7671244B2 (ja) | 2018-10-12 | 2025-05-01 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド |
| EP3867261B1 (fr) | 2018-10-19 | 2025-04-30 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs 9(11)-insaturés et leurs procédés d'utilisation |
| MX2021006618A (es) | 2018-12-05 | 2021-09-23 | Sage Therapeutics Inc | Esteroides neuroactivos y sus metodos de uso. |
| WO2020132504A1 (fr) | 2018-12-21 | 2020-06-25 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs de 3.alpha.-hydroxy-17.bêta.-amide et compositions associées |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| WO2020243488A1 (fr) | 2019-05-31 | 2020-12-03 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs et compositions associées |
| JP7670632B2 (ja) | 2019-06-27 | 2025-04-30 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を治療するための組成物及び方法 |
| US20230303616A9 (en) | 2019-06-27 | 2023-09-28 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2020264495A1 (fr) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compositions et méthodes de traitement de troubles du système nerveux central |
| KR20220112803A (ko) | 2019-12-05 | 2022-08-11 | 세이지 테라퓨틱스, 인크. | 19-nor c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법 |
| WO2021188778A2 (fr) | 2020-03-18 | 2021-09-23 | Sage Therapeutics, Inc. | Stéroïdes neuroactifs et leurs procédés d'utilisation |
| EP4125921A1 (fr) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Utilisation d'agents pour le traitement d'affections respiratoires |
| JP2023531517A (ja) | 2020-06-24 | 2023-07-24 | セージ セラピューティクス， インコーポレイテッド | ３．アルファ．－ヒドロキシ、１７．ベータ．－ｃ（ｏ）－ｎ－アリール置換神経活性ステロイド及びそれらの組成物 |
| BR112023000990A2 (pt) | 2020-07-20 | 2023-03-28 | Sage Therapeutics Inc | Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas |
| CA3202870A1 (fr) | 2020-11-25 | 2022-06-02 | Sage Therapeutics, Inc. | Compositions et methodes pour traiter les troubles du systeme nerveux central |
| JP2024507638A (ja) | 2021-01-28 | 2024-02-21 | セージ セラピューティクス， インコーポレイテッド | 性機能障害処置のための神経刺激性ステロイドの使用 |
| WO2022177718A1 (fr) | 2021-02-18 | 2022-08-25 | Sage Therapeutics, Inc. | Utilisation d'un stéroïde neuroactif pour le traitement d'un dysfonctionnement sexuel |
| CA3213744A1 (fr) | 2021-03-17 | 2022-09-22 | Sage Therapeutics, Inc. | Steroide 19-nor c3,3-disubstitue c21-n-pyrazolyl pour le traitement d'un trouble depressif majeur |
| CA3216542A1 (fr) | 2021-04-12 | 2022-10-20 | Sage Therapeutics, Inc. | Traitement de tremblements essentiels |
| WO2022232494A1 (fr) | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | Stéroïde neuroactif destiné à être utilisé dans le traitement d'un trouble dépressif majeur et de la dépression post-partum chez une femme allaitante |
| IL307991A (en) | 2021-04-29 | 2023-12-01 | Sage Therapeutics Inc | 19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression |
| KR20240148425A (ko) | 2022-02-16 | 2024-10-11 | 세이지 테라퓨틱스, 인크. | Cns-관련 장애의 치료를 위한 신경활성 스테로이드 |
| TW202341996A (zh) | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療腸胃疾病或病狀之神經活性類固醇 |
-
2017
- 2017-08-23 KR KR1020237017309A patent/KR20230079470A/ko active Pending
- 2017-08-23 EA EA201990565A patent/EA201990565A1/ru unknown
- 2017-08-23 EP EP21190443.8A patent/EP3981763A1/fr active Pending
- 2017-08-23 SG SG11201901445TA patent/SG11201901445TA/en unknown
- 2017-08-23 IL IL302480A patent/IL302480A/en unknown
- 2017-08-23 JP JP2019510657A patent/JP2019524853A/ja not_active Withdrawn
- 2017-08-23 NZ NZ791594A patent/NZ791594A/en unknown
- 2017-08-23 CN CN202210890054.4A patent/CN115974956A/zh active Pending
- 2017-08-23 CA CA3034262A patent/CA3034262A1/fr active Pending
- 2017-08-23 JO JOP/2019/0022A patent/JOP20190022B1/ar active
- 2017-08-23 CN CN202210890024.3A patent/CN115974954A/zh active Pending
- 2017-08-23 BR BR112019003637A patent/BR112019003637A2/pt not_active Application Discontinuation
- 2017-08-23 CN CN202210890025.8A patent/CN115974955A/zh active Pending
- 2017-08-23 EP EP17761714.9A patent/EP3504189A1/fr not_active Withdrawn
- 2017-08-23 KR KR1020197008069A patent/KR20190040043A/ko not_active Ceased
- 2017-08-23 MA MA046042A patent/MA46042A/fr unknown
- 2017-08-23 MX MX2019002193A patent/MX393240B/es unknown
- 2017-08-23 MY MYPI2019000844A patent/MY200479A/en unknown
- 2017-08-23 AR ARP170102330A patent/AR109393A1/es not_active Application Discontinuation
- 2017-08-23 US US16/326,977 patent/US11236121B2/en active Active
- 2017-08-23 PE PE2024000634A patent/PE20241580A1/es unknown
- 2017-08-23 CN CN201780063826.4A patent/CN110088091A/zh active Pending
- 2017-08-23 TW TW112101437A patent/TWI854445B/zh active
- 2017-08-23 TW TW106128611A patent/TWI808945B/zh active
- 2017-08-23 AU AU2017315682A patent/AU2017315682B2/en active Active
- 2017-08-23 PE PE2019000416A patent/PE20190915A1/es unknown
- 2017-08-23 IL IL315950A patent/IL315950A/en unknown
- 2017-08-23 WO PCT/US2017/048267 patent/WO2018039378A1/fr not_active Ceased
-
2019
- 2019-02-19 ZA ZA2019/01051A patent/ZA201901051B/en unknown
- 2019-02-21 PH PH12019500375A patent/PH12019500375A1/en unknown
- 2019-02-22 MX MX2022007432A patent/MX2022007432A/es unknown
- 2019-02-22 CL CL2019000477A patent/CL2019000477A1/es unknown
- 2019-03-20 CO CONC2019/0002596A patent/CO2019002596A2/es unknown
- 2019-03-22 EC ECSENADI201920141A patent/ECSP19020141A/es unknown
- 2019-12-10 CL CL2019003610A patent/CL2019003610A1/es unknown
-
2021
- 2021-08-06 US US17/396,464 patent/US11884696B2/en active Active
-
2022
- 2022-02-08 AU AU2022200811A patent/AU2022200811B9/en active Active
- 2022-04-08 AR ARP220100894A patent/AR125320A2/es unknown
- 2022-04-08 AR ARP220100895A patent/AR125321A2/es unknown
- 2022-11-07 JP JP2022178009A patent/JP2023002846A/ja active Pending
-
2023
- 2023-08-24 US US18/455,324 patent/US12358942B2/en active Active
-
2024
- 2024-02-06 AU AU2024200732A patent/AU2024200732A1/en active Pending
- 2024-05-07 JP JP2024075299A patent/JP2024097878A/ja active Pending
-
2025
- 2025-06-11 US US19/234,808 patent/US20250304615A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022007432A (es) | Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino. | |
| SA520411222B1 (ar) | مركبات بوصفها معدلات لعامل باديء حقيقي النواة 2ب وتركيبات وطرق | |
| PH12018500777A1 (en) | Farnesoid x receptor modulators | |
| MX2023000835A (es) | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y metodos de uso de este. | |
| EP4365179A3 (fr) | Nouveaux dérivés de rapamycine | |
| NZ747259A (en) | Soluble c5ar antagonists | |
| EP4609866A3 (fr) | Oxystérols et leurs procédés d'utilisation | |
| PH12019501639A1 (en) | Jaki selective inhibitors | |
| MX2021010418A (es) | Composiciones que comprenden una caseína y métodos para producir las mismas. | |
| PH12016502378A1 (en) | Substituted dihydroisoquinolinone compounds | |
| CA3010509A1 (fr) | Utilisation de derives de thiohydantoin substitue en tant qu'antagonistes des recepteurs d'androgenes | |
| MX2021008002A (es) | Sales nuevas y forma polimorfica del acido bempedoico. | |
| MX393879B (es) | Métodos de preparación de niraparib. | |
| AU2014324961A8 (en) | Highly potent glucocorticoids | |
| ZA202103228B (en) | Crystal forms of an alk2 inhibitor | |
| PH12016501483A1 (en) | P-substituted asymmetric ureas and medical uses thereof | |
| JOP20200030A1 (ar) | مركب خماسي الحلقة | |
| WO2018125880A8 (fr) | Activateur de nrf2 | |
| MX2019003684A (es) | Formas cristalinas de un derivado de acido biliar. | |
| MX374568B (es) | Formas sólidas que comprenden (1e, 4e)-2-amino-n,n-dipropil-8-(4-(pirrolidina-1-carbonil)fenil)-3h-benzo[b]azepina-4-carboxamida, composiciones de las mismas y usos de las mismas. | |
| WO2018165269A3 (fr) | Formes cristallines de l'acide obéticholique | |
| MA39877A (fr) | Formes solides d'un composé pharmaceutiquement actif | |
| PH12017501869A1 (en) | (s)-2'-vinyl-abscisic acid derivatives | |
| IN2014MU00859A (fr) | ||
| PH12019500801A1 (en) | Structures and mechanism for the design of highly potent glucocorticoids |